User shares progress update on hair loss treatment using finasteride, minoxidil, and microneedling. Others congratulate and ask questions about treatment details, such as microneedling tool, needle size, and side effects.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
The user shared their 6-month progress using 0.25 mg finasteride, topical minoxidil, and dermastamping, noting good results but experiencing increased sleepiness. Another user suggested minoxidil might be causing the sleepiness, and the original poster considered adjusting their treatment.
The conversation discusses hair loss treatment using 1ml of minoxidil twice daily and a 1.5mm dermaroller once a week. One person suggests considering finasteride, while another emphasizes the importance of microneedling in maintaining hair growth.
The conversation humorously discusses using semen as a topical treatment for hair growth, with users joking about its effectiveness and comparing it to other treatments like finasteride. The tone is light-hearted and sarcastic, with no serious endorsement of the method.
The conversation discusses the cost-effectiveness of using premade RU58841 versus making it from powder for hair loss treatment. It also questions whether higher concentrations are more effective for women.
A user is treating hair loss with oral finasteride, topical minoxidil, and tretinoin mixed with moisturizer for easier scalp application. They also plan to use a derma pen weekly.
People are discussing using tretinoin with minoxidil for hair loss treatment, focusing on application methods and results. Microneedling is mentioned as a separate method to promote hair growth, with some debate on its effectiveness in enhancing minoxidil absorption.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.